hematology

Blood diseases and blood cancers, such as sickle cell disease, anemia and myeloma, and treatments for them.

Theme · 11 companies · 3 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ADRX ADARx Pharmaceuticals, Inc.

    In development“In April 2026, we initiated an open-label Phase 2a clinical trial to evaluate the safety and tolerability of agazisiran in up to 24 participants with PNH and residual anemia.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops siRNA drugs for hereditary angioedema and other diseases; $446M all-primary raise funds clinical development

  • AMGN Amgen

    Sells it 12%, $4.5B a year“Nplate was launched in 2008 and is indicated to treat thrombocytopenia in patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.”

    Latest 10-QQ3 FY2026 ·

    Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.

    • Revenue$10.4BYoY +8.5%
    • Net income$3.9BYoY +20.1%
  • BLSM BlossomHill Therapeutics, Inc.

    In development“Our second clinical-stage product candidate, BH-30236, is a CLK inhibitor currently being evaluated in an ongoing Phase 1 clinical trial in patients with R/R AML and HR-MDS.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops small-molecule cancer drugs; $150M all-primary raise funds trials led by BH-30643 for treatment-resistant lung cancer.

  • BMY Bristol-Myers Squibb

    Sells it 21%, $10.3B a year“Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma.”

    Latest 10-QQ3 FY2026MixedImpairment / charge ·

    Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.

    • Revenue$13.1BYoY +6.9%
    • Net income$2.2BYoY −1.8%
  • CDNA CareDx, Inc

    Sells it“AlloSeq HCT is an NGS solution for chimerism testing for stem cell transplant recipients.”

    Latest 10-QQ3 FY2026Positive ·

    Naveris adds NavDx oncology testing as lab products exit; accelerating transplant demand and older-test revenue recognition fuel growth.

    • Revenue$139.4MYoY +39.3%
    • Net income$19.3Mvs $1.7M year ago
  • CTY CITY THERAPEUTICS, INC.

    In development“Our third program, CITY-TFR2, is a City-engineered GalNAc-conjugated siRNA therapeutic in development for anemia of chronic disease, which accounts for up to 40% of all anemias and affects more than five million people in the United States.”

    Latest 424B4final IPO prospectusCustomer concentration ·

    Develops RNA interference drugs led by CITY-FXI for thrombosis; raises $200M entirely through new shares.

  • ETRA Electra Therapeutics, Inc.

    In development“Patients with sHLH are typically diagnosed and treated by hematologist-oncologists in both outpatient and inpatient settings.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernPre-revenue ·

    Develops antibodies to remove disease-driving immune cells; $350M all-primary raise funds ipsoprubart’s registrational trials

  • MRK Merck & Co.

    Sells it <1%, $525.0M a year“alliance revenue related to Reblozyl (luspatercept-aamt) for the treatment of certain types of anemia.”

    Latest 8-KLeadership change ·

    Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.

  • SCTX Scribe Therapeutics, Inc.

    Supplies it“In our collaboration with Sanofi, we apply our XE technology to develop in vivo CRISPR-based therapies for sickle cell disease and other genetic diseases.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernCustomer concentration ·

    Develops CRISPR medicines to lower cholesterol; $129M all-primary raise funds STX-1150 trials and pipeline development.

  • STA Starton Holdings, Inc.

    In development“Based on the results of that evaluation, we are focused initially on the treatment of hematologic malignancies (blood cancers).”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issuePre-revenue ·

    Develops continuous-delivery lenalidomide for blood cancers; offering funds trials but further capital is needed to reach approval

  • VRTX Vertex Pharmaceuticals

    Sells it“CASGEVY’s label expanded in the U.S. to children aged two and older with sickle cell disease or transfusion-dependent beta thalassemia.”

    Latest 10-QQ3 FY2026Positive ·

    Crinetics adds an endocrine franchise, but deal costs and launch spending squeeze profit despite ALYFTREK-led sales growth.

    • Revenue$3.4BYoY +11.8%
    • Net income$653.6MYoY −39.6%

Feedback